ALKS Alkermes plc

Price (delayed)

$19.45

Market cap

$3.1B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.7

Enterprise value

$3.23B

Sector: Healthcare
Industry: Biotechnology

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights

The EPS has dropped by 52% since the previous quarter but it is up by 44% year-on-year
Alkermes's net income has plunged by 51% from the previous quarter but it has increased by 44% YoY
The debt has grown by 41% YoY and by 6% from the previous quarter
Alkermes's gross profit has decreased by 13% YoY and by 13% from the previous quarter

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
159.24M
Market cap
$3.1B
Enterprise value
$3.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.9
Price to sales (P/S)
2.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
Earnings
Revenue
$1.04B
EBIT
-$87.88M
EBITDA
-$6.02M
Free cash flow
$41.27M
Per share
EPS
-$0.7
Free cash flow per share
$0.26
Book value per share
$6.7
Revenue per share
$6.54
TBVPS
$10.99
Balance sheet
Total assets
$1.95B
Total liabilities
$882.75M
Debt
$410.16M
Equity
$1.07B
Working capital
$672.71M
Liquidity
Debt to equity
0.38
Current ratio
2.53
Quick ratio
2.08
Net debt/EBITDA
-22.77
Margins
EBITDA margin
-0.6%
Gross margin
82.8%
Net margin
-10.7%
Operating margin
-10.8%
Efficiency
Return on assets
-5.9%
Return on equity
-10.4%
Return on invested capital
-6.1%
Return on capital employed
-5.8%
Return on sales
-8.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
-2.16%
1 week
-1.07%
1 month
-14.95%
1 year
-2.41%
YTD
-2.51%
QTD
-2.51%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.04B
Gross profit
$860.44M
Operating income
-$112.43M
Net income
-$110.86M
Gross margin
82.8%
Net margin
-10.7%
The net margin has plunged by 70% from the previous quarter but it has grown by 36% YoY
Alkermes's net income has plunged by 51% from the previous quarter but it has increased by 44% YoY
The company's operating margin fell by 38% QoQ but it rose by 28% YoY
Alkermes's operating income has increased by 36% YoY but it has decreased by 23% from the previous quarter

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
P/E
N/A
P/B
2.9
P/S
2.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
The EPS has dropped by 52% since the previous quarter but it is up by 44% year-on-year
The P/B is 41% lower than the 5-year quarterly average of 4.9 but 12% higher than the last 4 quarters average of 2.6
ALKS's P/S is 54% below its 5-year quarterly average of 6.5 but 19% above its last 4 quarters average of 2.5
The revenue has contracted by 11% from the previous quarter and by 11% YoY

Efficiency

How efficient is Alkermes business performance
The ROS has dropped by 107% since the previous quarter but it is up by 46% year-on-year
The ROIC has plunged by 79% from the previous quarter but it has soared by 59% YoY
The return on equity has dropped by 51% since the previous quarter but it has increased by 43% year-on-year
The ROA fell by 48% QoQ but it rose by 47% YoY

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 121% higher than its total liabilities
The company's total liabilities rose by 23% YoY and by 11% QoQ
Alkermes's total assets has increased by 8% YoY and by 3.9% QoQ
The debt is 62% less than the equity
The debt has grown by 41% YoY and by 6% from the previous quarter
The debt to equity is up by 41% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.